Angiogenesis is a typical process, which underlies cancer, rheumatoid arthritis and the majority of blinding ocular disorders. The ability to selectively target and/or ablate new blood vessels will open diagnostic and therapeutic opportunities. Recently, our network has collaborated for the isolation of antibodies (Abs), which selectively recognise new-forming blood vessels. Two good-quality rankers of angiogenesis have been identified. The corresponding high-affinity phage Abs, efficiently target tumour neovasculature in vivo. We now propose to chemically modify anti-angiogenesis Abs and to test the biomedical potential of their conjugates. In particular, we will use radionuclides and fluorophores to investigate the potential of our labelled Abs for image diagnostics. We will also couple them to drugs, cytokines etc. and evaluate their therapeutic potential in suitable animal models. We will continue to search for novel markers of angiogenesis.
Funding SchemeCSC - Cost-sharing contracts